GlobeNewswire: Cancer Genetics, Inc. Contains the last 10 of 244 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T06:32:17ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2019/08/20/1904086/0/en/Cancer-Genetics-Reports-Second-Quarter-2019-Financial-Results-and-Provides-Strategic-Business-Update.html?f=22&fvtc=4&fvtv=19819Cancer Genetics Reports Second Quarter 2019 Financial Results and Provides Strategic Business Update2019-08-20T12:00:00Z<![CDATA[RUTHERFORD, N.J., Aug. 20, 2019 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced strategic, financial and operating results for the second quarter ended June 30, 2019.]]>https://www.globenewswire.com/news-release/2019/07/15/1882947/0/en/Cancer-Genetics-Inc-Announces-Strategic-Transactions.html?f=22&fvtc=4&fvtv=19819Cancer Genetics, Inc. Announces Strategic Transactions2019-07-15T20:22:03Z<![CDATA[Sale of BioPharma business to Interpace Diagnostics Group, Inc.]]>https://www.globenewswire.com/news-release/2019/05/20/1829200/0/en/Cancer-Genetics-Reports-First-Quarter-2019-Financial-Results-and-Provides-Strategic-Business-Update.html?f=22&fvtc=4&fvtv=19819Cancer Genetics Reports First Quarter 2019 Financial Results and Provides Strategic Business Update2019-05-20T21:00:00Z<![CDATA[RUTHERFORD, N.J., May 20, 2019 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through diagnostics, molecular markers and data solutions, today announced financial and operating results for the first quarter ended March 31, 2019.]]>https://www.globenewswire.com/news-release/2019/04/16/1804589/0/en/Cancer-Genetics-Reports-Fourth-Quarter-and-Full-Year-2018-Financial-Results-and-Provides-Strategic-Business-Updates.html?f=22&fvtc=4&fvtv=19819Cancer Genetics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Strategic Business Updates2019-04-16T11:00:00Z<![CDATA[RUTHERFORD, N.J., April 16, 2019 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through diagnostics, molecular markers and data solutions, today announced financial and operating results for the fourth quarter and full year ended December 31, 2018.]]>https://www.globenewswire.com/news-release/2019/01/31/1708763/0/en/Cancer-Genetics-Inc-Announces-Closing-of-Public-Offering-of-Common-Stock.html?f=22&fvtc=4&fvtv=19819Cancer Genetics, Inc. Announces Closing of Public Offering of Common Stock2019-01-31T21:01:00Z<![CDATA[RUTHERFORD, N.J., Jan. 31, 2019 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular markers and diagnostics, today announced the closing and funding of its previously announced public offering of 15,217,392 shares of its common stock ("Common Stock") at a public offering price of $0.23 per share. The Company’s Chairman, John Pappajohn; board director, Ted Cannon; Chief Financial Officer, Glenn Miles; and President and Chief Executive Officer, John A. Roberts, each purchased shares in the offering. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and estimated offering expenses are approximately $3.5 million.]]>https://www.globenewswire.com/news-release/2019/01/29/1706523/0/en/Cancer-Genetics-Inc-Announces-Pricing-of-3-5-Million-Public-Offering-of-Common-Stock.html?f=22&fvtc=4&fvtv=19819Cancer Genetics, Inc. Announces Pricing of $3.5 Million Public Offering of Common Stock2019-01-29T03:33:52Z<![CDATA[RUTHERFORD, N.J., Jan. 28, 2019 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular markers and diagnostics, today announced the pricing of a public offering of 15,217,392 shares of its common stock, offered at a price to the public of $0.23 per share, for gross proceeds of approximately $3.5 million, before deducting placement agent fees and other offering expenses payable by Cancer Genetics. The offering is expected to close on or about January 31, 2019, subject to customary closing conditions.]]>https://www.globenewswire.com/news-release/2019/01/28/1706406/0/en/Cancer-Genetics-Inc-Announces-Proposed-Public-Offering-of-Common-Stock.html?f=22&fvtc=4&fvtv=19819Cancer Genetics, Inc. Announces Proposed Public Offering of Common Stock2019-01-28T21:00:00Z<![CDATA[RUTHERFORD, N.J., Jan. 28, 2019 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular markers and diagnostics, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in a public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.]]>https://www.globenewswire.com/news-release/2019/01/16/1696747/0/en/Cancer-Genetics-Issues-Letter-to-Shareholders.html?f=22&fvtc=4&fvtv=19819Cancer Genetics Issues Letter to Shareholders2019-01-16T13:45:00Z<![CDATA[RUTHERFORD, N.J., Jan. 16, 2019 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular markers and diagnostics, today published a letter to shareholders from its Chief Executive Officer, Jay Roberts.]]>https://www.globenewswire.com/news-release/2019/01/14/1691340/0/en/Cancer-Genetics-Inc-Announces-Closing-of-Public-Offering-of-Common-Stock.html?f=22&fvtc=4&fvtv=19819Cancer Genetics, Inc. Announces Closing of Public Offering of Common Stock2019-01-14T22:29:31Z<![CDATA[RUTHERFORD, N.J., Jan. 14, 2019 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular markers and diagnostics, today announced the closing and funding of its previously announced underwritten public offering of 13,333,334 shares of its common stock ("Common Stock") at a public offering price of $0.225 per share. The Company has also granted the underwriter an option for 45 days to purchase an additional 2,000,000 shares, at a price to the public of $0.225 per share. The Company’s Chairman, John Pappajohn; board director, Geoffrey Harris and President and Chief Executive Officer, John A. Roberts, each purchased shares in the offering. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and estimated offering expenses are $3.0 million.]]>https://www.globenewswire.com/news-release/2019/01/10/1685900/0/en/Cancer-Genetics-Inc-Announces-Pricing-of-Public-Offering-of-Common-Stock.html?f=22&fvtc=4&fvtv=19819Cancer Genetics, Inc. Announces Pricing of Public Offering of Common Stock2019-01-10T04:20:25Z<![CDATA[RUTHERFORD, N.J., Jan. 09, 2019 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular markers and diagnostics, today announced the pricing of an underwritten public offering of 13,333,334 shares of its common stock at a price to the public of $0.225 per share. Cancer Genetics also granted the underwriter a 45-day option to purchase up to an additional 2,000,000 shares of its common stock at the public offering price of $0.225 per share, less underwriting discounts and commissions. Cancer Genetics expects to receive aggregate gross proceeds of approximately $3.0 million from the offering, assuming no exercise of the underwriter’s option to purchase additional shares. The offering is expected to close on or about January 14, 2019, subject to customary closing conditions.]]>